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One of the features of primate immunodeficiency viruses (HIVs and SIVs) that distinguishes them from other
retroviruses is the array of ‘‘accessory’’ proteins they encode. Here, we discuss recent advances in under-
standing the interactions of the HIV-1 Nef, Vif, Vpu, and Vpr proteins with factors and pathways expressed
in cells of the immune system. In at least three instances, the principal activity of the accessory proteins
appears to be evasion fromvarious formsof cell-mediated (or intrinsic), antiviral resistance. Broadly speaking,
the HIV-1 accessory proteins modify the local environment within infected cells to ensure viral persistence,
replication, dissemination, and transmission.Introduction
The retrovirus that causes AIDS, human immunodeficiency virus
type-1 (HIV-1), not only persists by populating sanctuary sites
throughout the body but also employs multiple genetic strate-
gies that, together, contribute to lifelong infection after success-
ful transmission. First, by irreversibly integrating its viral DNA into
the host cell genome to establish the provirus, HIV-1 safeguards
its survival for the lifetime of the infected cell. Second, viral se-
quence diversification during spreading infection allows the virus
to escape or tolerate adaptive immune responses. And, third,
despite its compact genome comprising just nine genes, four
of these (nef, vif, vpu, and vpr) now appear to be dedicated to
various aspects of evasion from (and manipulation of) adaptive
and innate immunity. Indeed, as has been recognized for other
viruses (e.g., poxviruses and herpes viruses), these viral immu-
nomodulatory genes are frequently seen as dispensable in
many in vitro cell culture systems—leading to their loss during
long-term propagation—yet are strongly maintained in the con-
text of natural infections in vivo.
The reliance of HIV-1 upon numerous cellular host factors for
nearly every step of viral replication is well appreciated (Brass
et al., 2008; Swanson and Malim, 2008). In many cases, the roles
of viral proteins are to recruit already assembled cellular machin-
ery to perform essential roles in the virus life cycle. For example,
one of the Gag proteins, p6, interacts with ESCRT complexes
during virus assembly to facilitate viral budding, and the Rev pro-
tein recruits nuclear export factors to allow the nucleocytoplas-
mic transport of unspliced viral RNA. In contrast, a more recently
appreciated phenomenon is the role of HIV-1 proteins in antag-
onizing host proteins that have evolved to defend against retro-
viral infections via diverse, cell-autonomous mechanisms: these
have variously been called either intrinsic immunity factors or re-
striction factors. Here, we review how the Vif and Vpu (and prob-
ably Vpr) proteins each suppress the antiviral activity of specific
restriction factors, whereas the multifunctional Nef protein con-388 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.tributes, inter alia, to partial evasion from adaptive, cell-mediated
immunity. In addition to describing recent advances in our mech-
anistic understanding of these host-pathogen interactions, we
will speculate on the importance of maintaining a balance be-
tween host and viral functions, discuss potential implications
for viral zoonoses, and highlight some important questions for
the future.
Proteasome-Mediated Degradation: A Frequent
Viral Target
A recurring theme throughout this review is the use of protein
degradation, and in particular cullin-RING finger ubiquitin ligases
(Petroski and Deshaies, 2005), to avert the action of host proteins
that interfere with HIV-1 replication. More specifically, Vif, Vpu,
and Vpr all link to members of this superfamily of modular ubiq-
uitin ligases to induce the polyubiquitylation and proteasomal
degradation of their cellular targets (Table 1). At the heart of
each cullin-RING ubiquitin ligase is a cullin—of which there are
seven in vertebrates—that serves as a central scaffold. The C-
terminal region of cullins binds an Rbx/Roc RING finger protein
and recruits an E2 conjugating enzyme to form the catalytic
core of the enzyme. The N terminus binds to an adaptor protein
(e.g., Skp1), which, in turn, recruits a further subunit that func-
tions as the receptor for substrate binding (e.g., b-TrCP). As sub-
strates (e.g., Vpu) engage their receptors, they are brought into
the proximity of the E2 subunit such that they and/or additional
interacting proteins (e.g., CD4, the cell surface receptor for
HIV-1) are ubiquitylated by a poorly understood process that
also involves the cullin-RING finger region. By mixing and match-
ing the wide variety of different ligase subunits, it is easy to see
how one regulatory pathway (ubiquitylation and degradation)
can be coupled to a tremendous diversity of protein interaction
sites. This feature has been exploited by (at least) three HIV-1 ac-
cessory proteins to ensure that an otherwise hostile intracellular
environment becomes conducive to effective viral replication
and spread.
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ReviewFigure 1. HIV-1 Nef and Vpu Regulate the Surface Expression and Localization of Host Cell Membrane Proteins
The effects of Nef on MHC class I are specific for HLA-A/B; the -C/E allotypes are not affected as their presence on the cell surface is important for protection from
NK-mediated killing. ER, endoplasmic reticulum; IS, immunological synapse; APC, antigen presenting cell.Modulation of Host Cell Surface Molecules: Nef and Vpu
Cell surface interactions are crucial for the life cycle and survival
of any intracellular parasite. In the case of HIV-1, the virus enters
target cells at their surface using the entry receptor CD4, and the
coreceptors CCR5 or CXCR4 and newly synthesized viral parti-
cles bud from and are released from the surface of infected cells.
However, the cell surface is also where the adaptive immune
response recognizes virally infected cells in the context of viral
epitopes presented by major histocompatibility class I com-
plexes (MHC class I). Thus, viral accessory proteins that modu-
late the cell surface both aid certain virus replication steps that
occur there, and also help the virus evade immune recognition.
Such is the case for the Nef and Vpu proteins of HIV-1, which
regulate the activity, localization, and abundance of surface
membrane proteins in ways that profoundly influence viral repli-
cation, dissemination, and persistence.
Nef is a 27 kD myristoylated protein that is associated with
the cytoplasmic face of cellular membranes. It is one of the first
viral proteins to be expressed following infection, implying
perhaps that it plays an important role in helping set the tempo
or magnitude of infectious virus propagation. Despite its seem-
ingly erroneous name (negative factor), the importance of
Nef as a critical determinant of pathogenicity has been estab-
lished through the observed long-term survival of humans or
rhesus macaques infected with HIV-1 or SIV (simian immuno-
deficiency virus) strains lacking intact nef genes (Deacon
et al., 1995), a view that is further supported by recent work
indicating that Nef may help dictate pathogenic outcome in
natural infections of different species of primates (Schindler
et al., 2006).The intracellular trafficking of a number of cell surface proteins
of helper T cells and macrophages (the targets of HIV-1 infection)
with central roles in immunity and the virus life cycle is regulated
by Nef (Roeth and Collins, 2006). Prominent among these is CD4,
the primary entry receptor for this virus. It has long been known
that the endocytosis of CD4 from the surface of infected cells is
accelerated in response to Nef. This occurs through the interac-
tion of Nef with the cytoplasmic tail of CD4, the recruitment of
AP2 (clathrin adaptor protein complex 2), internalization through
clathrin coated pits, and subsequent transport to endosomes
and then lysozomes for degradation (Figure 1) (Chaudhuri
et al., 2007). The involvement of a number of other participants
in vesicular trafficking has been documented (Roeth and Collins,
2006), but a complete understanding of their respective roles in
CD4 regulation is awaited.
Importantly, HIV-1 also employs another accessory protein,
Vpu, to reduce the surface expression of CD4 (Figure 1) (a sec-
ond major activity of Vpu is discussed in the following section).
Vpu is an 81 amino acid dimeric integral membrane protein
that induces the turnover of CD4 by recruiting a cullin1-Skp1
ubiquitin ligase complex to the cytoplasmic tail of CD4 (Table 1)
(Margottin et al., 1998). Like Nef, Vpu interacts with the cytoplas-
mic tail of CD4, but in this case the interaction is with CD4 that
has been retained in the endoplasmic reticulum (ER) by binding
to the nascently synthesized viral Env glycoprotein, gp160, that
would otherwise traffic to the cell surface for incorporation into
assembling virus particles. As noted above, Vpu also binds to
the Skp1-binding receptor protein, b-TrCP, thereby connecting
the ligase complex to the cytoplasmic tail of CD4 and triggering
polyubiquitylation and proteasomal degradation. The mechanismCell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 389
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ReviewTable 1. HIV-1 Accessory Proteins Recruit Cullin-RING Finger Ubiquitin Ligases to Eliminate Host Cell Proteins that Impede
Replication
Accessory Protein Cellular Substrate(s) Receptor Protein Adaptor Protein(s) Cullin Scaffold Benefit to Virus
Vif APOBEC3G;
APOBEC3F
none elongin B/C cullin5 protection from APOBEC-mediated
inhibition and G-to-A hypermutation
Vpu CD4 b-TrCP Skp1 cullin1 efficient release of virus particles
from infected cells
Vpr (and Vpx) unknown DCAF1(VprBP) DDB1 cullin4A G2/M arrest; suppression of
postentry ‘‘restriction’’for extracting CD4 from the ER membrane is not yet fully under-
stood, with evidence for and against a dependence upon ER-as-
sociated protein degradation (ERAD) components having been
described (Binette et al., 2007; Meusser and Sommer, 2004). Ul-
timately, because two different HIV-1 accessory proteins con-
tribute to the downregulation of CD4 from the cell surface, it is
logical to infer that this must be important for viral propagation:
for instance, cultured cell assays where surface interactions be-
tween CD4 and Env have been prevented show enhancements
in virus release and Env incorporation (Lama et al., 1999; Ross
et al., 1999). Consistent with this, experimental challenges of
rhesus macaques with SIV carrying nef mutations that prevent
Nef-AP2 interactions result in less virulent infections with lower
viral loads (Brenner et al., 2006). However, these effects are dif-
ficult to assign to specific molecular defects, as other attributes
of Nef such as effects on other cell surface proteins and/or viral
infectivity (see below) were also influenced by these mutations.
MHC class I and specifically the HLA-A and -B allotypes, are
also downregulated from the surface of HIV-1 infected cells by
Nef (Roeth and Collins, 2006). Two alternative mechanisms
have been proposed for this (Figure 1): first, Nef interacts with
the cytoplasmic tail of HLA-A/B and recruits AP1 complexes to
mis-route MHC class I from the trans-Golgi network to endo-
somes (rather than to the cell surface) (Lubben et al., 2007; Nov-
iello et al., 2008; Roeth et al., 2004); or, second, Nef assembles
a multicomponent Src-family kinase containing cascade to in-
duce the endocytosis of MHC class I from the cell surface (Atkins
et al., 2008). Irrespective of the precise mechanism, it seems
plausible that it would be a selective advantage for the virus to
suppress MHC class I function in order to blunt cytotoxic T cell
(CTL) recognition of infected cells. This is supported by data
from the rhesus macaque/SIV model showing that mutations in
nef that prevent (solely) MHC class I downregulation are associ-
ated with heightened SIV-specific CTL responses or by muta-
tions in nef that restore downregulation (Swigut et al., 2004).
However, paradoxically, HIV-1 and SIV mutations driven by es-
cape from CTL recognition are well described in the HIV-1 liter-
ature (Goulder and Watkins, 2004), implying that the presenta-
tion of viral epitopes by MHC class I continues throughout the
course of infection. Thus, although the ability of Nef to down-
regulate MHC class I is well conserved during natural infection
and across multiple lineages of primate lentiviruses (Lewis
et al., 2008; Specht et al., 2008), in reality this effect can only
be partial in vivo, thus making mutation-assisted escape from
CTL recognition a critical driver of immune evasion.
A third cell surface complex that has emerged as a target for
Nef regulation is the T cell receptor (TCR-CD3). TCR-CD3 is
a critical component of the ‘‘immunological synapse’’ that forms390 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.between antigen-presenting cells (APCs) and T cells for antigen
recognition and sustained T cell activation. In mixed cell culture
systems in which antigen-pulsed APCs contact HIV-1 infected T
cells and form immunological synapses, the endocytosis of
TCR-CD3 from the cell surface and its transport through recy-
cling endosomes were retarded by Nef (Thoulouze et al.,
2006). This results not only in reduced clustering of TCR-CD3
at the immunological synapse, but also in inefficient synapse for-
mation (Figure 1). Comparatively less is known about the molec-
ular interactions that govern TCR-CD3 regulation by Nef, though
Nef has been shown to: interact with the z chain of CD3 (Howe
et al., 1998); induce the accumulation of Lck, a kinase important
for sustained signaling from the immunological synapse, in the
recycling endosome (Thoulouze et al., 2006); and inhibit the
activity of N-WASP, a positive regulator of actin polymerization
and critical mediator of T cell activation (Haller et al., 2006).
It has been proposed that differences in the capacity of Nef
proteins from different primate lentiviruses (which comprise
HIV-1, HIV-2, and many SIVs) to downregulate TCR-CD3 may
play a central role in dictating pathogenic outcome (Schindler
et al., 2006). The SIVs are generally not pathogenic in their natu-
ral hosts, but, like HIV-1 in humans, can be pathogenic when
transferred to a novel host species. Indeed, for the majority of
SIV/HIV Nef proteins tested, the capacity to downregulate
TCR-CD3 in human T cells correlated with a lack of both T cell
activation and pathogenicity during infection of the natural host
with the corresponding virus. For instance, Nef proteins derived
from nonpathogenic SIVs such as the virus found in African
green monkeys (SIV-AGM) are very effective at removing TCR-
CD3 from the cell surface. In contrast, the action of HIV-1 Nef ap-
pears to be more subtle: while it appears to negatively regulate
the movement of TCR-CD3 to the synapse (Figure 1), it does
not inhibit the overall cell surface expression of TCR-CD3. By
perturbing TCR-CD3 trafficking in this manner, the capacity of
T cells to respond to activation cues from APCs is diminished
(Thoulouze et al., 2006). Why would dampening T cell activation,
a process that stimulates virus replication, be advantageous for
the virus? One possibility is that by extending the survival of in-
fected cells, and perhaps inhibiting homeostatic processes
such as apoptosis (Geleziunas et al., 2001), Nef may balance T
cell activation to limit the deleterious effects of infection on
host immunity, while helping ensure prolonged (albeit less ram-
pant) viral production and long-term persistence. Nonetheless,
it should be pointed out that either through differences in exper-
imental systems, or perhaps variations in the phenotypes of dif-
ferent HIV-1 nef alleles, some apparently conflicting ideas re-
garding the functional consequences (impaired or enhanced T
cell activation) (Fenard et al., 2005; Haller et al., 2006; Thoulouze
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The inset depicts the genomic organization of HIV-1 and highlights the presence of accessory genes.et al., 2006) of the influence of Nef on TCR-CD3 remain. In addi-
tion, a positive correlation between Nef and a significant defect in
T cell responses to viral epitopes presented by APCs in vivo re-
mains to be demonstrated.
In addition to Env/CD4-associated effects that modulate HIV-
1 infectivity, Nef further enhances HIV-1 infectivity by facilitating
viral core penetration of the cortical actin network during the ini-
tial phases of infection. Recent new insight into this enigmatic
phenotype comes from the finding that dynamin 2, a GTPase
that is required for clathrin-mediated endocytosis, interacts
with Nef and is essential for Nef’s effect on infectivity (Figure 1)
(Pizzato et al., 2007). While the molecular basis for this is ob-
scure, it has been suggested that the recruitment of dynamin 2
by Nef to certain membranes, and perhaps sites of viral assem-
bly and budding, may manipulate the local composition of such
membranes and, hence, of progeny virus particles themselves
(Pizzato et al., 2007). Taken together, it is evident that Nef
manipulates the composition of the infected cell surface in a
variety of ways that may benefit viral propagation. Major chal-
lenges for the future include defining which of these (as well as
other) demonstrable—and in some cases seemingly oppos-
ing—phenotypes are important in the context of natural infec-
tion, and determining how they integrate with each other with
respect to various pathogenic outcomes, immune evasion, and
viral replication.
Modulation of Antiviral Activities at theCell Surface: Vpu
Type 1 interferons induce a large number of host genes with
diverse antiviral functions. The effects of such activities on HIV-1
include the inhibition of late stages of replication and, in the caseof interferon-a, the dramatic attachment of fully assembled HIV-1
particles to the surface of infected cells (Neil et al., 2007). Experi-
mentally, particles retained in this manner can be liberated by
adding a protease, suggesting that a protein linkage ‘‘tethers’’
them to the cell surface (Neil et al., 2006). Significantly, this restric-
tion to the release of viruses that have completed membrane
fission can be completely overcome by the HIV-1 Vpu protein
(Figure 2).
The influence of Vpu is cell-type specific: some cells require
Vpu for virus release, while others do not. By employing classical
cell fusions between cells in which efficient release is Vpu depen-
dent or Vpu independent, it was shown that the Vpu-depen-
dency phenotype is dominant, indicating that such cells express
Vpu-sensitive cellular factor(s) that prevent HIV-1 release (Var-
thakavi et al., 2003). The interferon-induced restriction factor
that prevents retrovirus release from the plasma membrane,
and is counteracted by Vpu, was recently identified (Neil et al.,
2008; Van Damme et al., 2008) as a cellular protein of previously
unknown function called B cell stromal factor 2 (BST-2) or
CD317: it has also been called ‘‘tetherin’’ to reflect its antiviral
activity (Neil et al., 2008).
Tetherin is a heavily glycosylated membrane protein that is
anchored to lipid bilayers both by an N-terminal transmembrane
region, and by a C-terminal glycosylphosphatidylinositol (GPI)
linker; thus, its N terminus is predicted to be cytosolic with the
remainder of the protein positioned on the outside of the
membrane (Kupzig et al., 2003). Its cellular localization is also
known to be highly dynamic, with a plasma membrane pool
that is associated with lipid rafts but continuously internalizedCell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 391
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made in the absence of Vpu in tetherin-expressing cells still
form at the plasma membrane with similar kinetics as virions
made in the presence of Vpu. However, the failure of these par-
ticles to be released results not only in their striking accumulation
at the exterior of the cell, but also in subsequent transport to
endosomes (Neil et al., 2006).
It is not yet clear how tetherin prevents virus release; however,
the mechanism must be relatively nonspecific since tetherin
affects the release of very distinct classes of virus. For example,
tetherin blocks the release of diverse retroviruses as well as
Ebola virus-like particles (Gottlinger et al., 1993; Neil et al.,
2007), and it is likely that it affects the Kaposi’s sarcoma-asso-
ciated herpesvirus (KSHV) since this virus encodes a protein,
K5, that induces the degradation of tetherin (Bartee et al.,
2006). It therefore seems unlikely that there is specific recogni-
tion between tetherin and viral structural proteins. One espe-
cially intriguing hypothesis derives from the notion that tetherin
serves to link cholesterol-rich lipid rafts together on the plasma
membrane (Kupzig et al., 2003): Accordingly, since many envel-
oped viruses, and HIV-1 in particular, are known to accumulate
and bud from lipid raft-rich regions of the plasma membrane,
tetherin may form connections between lipid rafts on plasma
and viral membranes and thereby physically prevent virus
egress.
It is also not yet evident how Vpu counteracts tetherin function.
Given that Vpu induces the proteasomal degradation of CD4 and
the KSHV K5 protein is a RING-type ubiquitin ligase, it made
sense that Vpu might also target tetherin for degradation. How-
ever, although overexpressed Vpu has been reported to reduce
tetherin expression levels (Bartee et al., 2006), the physiological
pertinence of this remains questionable since similar effects
have not been observed in the context of HIV-1 infection (Neil
et al., 2008). Moreover, the CD4 degradation function of Vpu (de-
scribed above) is dispensable for the ability of Vpu to enhance
virus release (Schubert et al., 1996). What currently seems more
likely is that Vpu either interferes with tetherin function directly
and/or alters the trafficking of tetherin between different cytoplas-
mic sites. By colocalizing closely with tetherin at various cellular
membranes (Neil et al., 2008; Van Damme et al., 2008), Vpu ap-
pears to be appropriately placed to interact with tetherin (either
directly or indirectly) and influence activity or localization. In keep-
ing with the second possibility, Vpu significantly reduces the sur-
face expression of tetherin (Van Damme et al., 2008) as well as its
colocalization with the HIV-1 Gag protein (Neil et al., 2008), and
disruption of protein sorting through early/recycling endosomes
has been shown to prevent Vpu-induced virus release (Varthakavi
et al., 2006). Thus, Vpu can be considered to be somewhat anal-
ogous to Nef in that it may modulate the subcellular compartmen-
talization of a host membrane protein to help promote viral dis-
semination and replication. Important next steps in this area are
to elucidate tetherin function in molecular terms, determine
whether Vpu influences this directly, and identify the trafficking
pathways and connecting factors that underlie the ability of Vpu
to overcome tetherin. It will also be interesting to see if the capac-
ity of Vpu function as an ion channel (a ‘‘viroporin’’) is important for
the suppression of tetherin since a number of other viruses also
encode viroporins that play roles in virus release and/or protein
trafficking (Gonzalez and Carrasco, 2003).392 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.Since tetherin is induced by interferon-a, it is almost certainly
part of a broad antiviral defense system that retains budding vi-
ruses on the surfaces of cells. Such a system might play a direct
role in increasing the likelihood that viral antigens will be better
presented to the adaptive immune system, or its existence
may reflect an evolutionary selection to prevent long-range virus
transmission between hosts (although under certain experimen-
tal selective pressures, retention of virus particles on the cell sur-
face actually increases cell-to-cell transmission [Gummuluru
et al., 2000]). Thus, one might anticipate that the ability of HIV-1
Vpu to counteract tetherin is not unique: indeed, as well as the
KHSV K5 protein described above, the HIV-2 Env protein also
stimulates virus release (Bour and Strebel, 1996). In addition,
because cells from AGMs encode an interferon-inducible factor
(presumably the AGM version of tetherin) that is effective against
HIV-1, yet is not overcome by Vpu (Neil et al., 2007), it is most
likely that this form of cell-mediated viral inhibition is an ancient
one and that the evolution of Vpu is one of the critical factors that
allowed the SIVs that are direct ancestors of HIV-1 to become
established in chimpanzees and gorillas, and then, ultimately,
in humans.
Inhibition of Cytoplasmic Defenses: Vif
The HIV-1 Vif protein (virion infectivity factor) is 192 amino acid
cytoplasmic protein whose essential role in replication in primary
T cells and during natural infection has long been established.
Though certain cultured cell lines are able to support growth of
vif-deficient viruses, cell fusion experiments indicated that
such cells lack expression of inhibitory factor(s) that naturally
block viral replication when Vif is absent. By comparing mRNA
expression profiles in cells where Vif is, or is not, required for
HIV-1 replication, the human gene APOBEC3G (A3G) was iden-
tified as being fully sufficient to prevent productive infection in
the absence of Vif (Sheehy et al., 2002).
The rather cumbersome name for this protein, apolipoprotein B
mRNA-editing enzyme catalytic polypeptide-like 3G, provided an
immediate clue regarding the possible mechanism for viral
suppression. Specifically, A3G is a member of the APOBEC fam-
ily of editing enzymes, many of which can mutate polynucleotides
by deaminating cytidine (C) to uridine (U) (Conticello et al., 2005;
Harris and Liddament, 2004; Holmes et al., 2007b). Indeed, in the
absence of Vif, newly synthesized A3G is packaged into budding
viral particles through a combination of A3G-RNA and A3G-Gag
interactions (Bogerd and Cullen, 2008; Soros et al., 2007) and
consequently carried forward to newly infected cells where it de-
aminates C residues to U residues in nascent minus (first) strand
reverse transcripts (Conticello et al., 2005; Harris and Liddament,
2004; Holmes et al., 2007b). Should these changes become
fixed, they register as guanosine (G)-to-adenosine (A) transitions
in plus strand sequence: since 10% of G residues can be mu-
tated, this phenomenon is called G-to-A hypermutation and, by
itself, is sufficient to stop further viral spread through the gross
loss of genetic integrity (a form of error catastrophe). Indeed,
evidence from examining the fossil record of endogenous retro-
viruses in the genome of mice and humans indicates that some
‘‘ancient’’ retroviral infections were inactivated by APOBEC3-
mediated mutations (Esnault et al., 2005; Jern et al., 2007; Y.N.
Lee, M.H.M., and P.D. Bieniasz, unpublished data).
In the majority of wild-type viral infections, Vif effectively an-
tagonizes the antiviral effects of A3G through the recruitment
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tylation (of A3G and Vif itself) and degradation (Table 1; Figure 2)
(Mehle et al., 2004; Yu et al., 2003). In the case of A3G, Vif simul-
taneously binds to a specific region of A3G centered around an
aspartic acid residue at position 128, as well as to the elonginC
and cullin5 components of the cullin5-elonginB/C complex, via
its BC box (a peptide motif that binds elonginB/C) and a zinc co-
ordinating motif, respectively (Huthoff and Malim, 2007; Mehle
et al., 2006; Yu et al., 2004). By eliminating A3G from virus-pro-
ducing cells, and perhaps by impeding packaging via a more
direct mechanism, Vif therefore allows progeny particles to be
produced that are free of A3G. Interestingly, phosphorylation
of a conserved serine in Vif’s BC box inhibits binding to elonginC
(Mehle et al., 2004), suggesting that the degradation of A3G in in-
fected cells may also be regulated by signaling pathways that
have yet to be explored in detail.
Like aspects of Nef biology described above (Schindler et al.,
2006), Vif function is also species specific. Vif proteins from HIVs
and SIVs whose ancestors have established infections in
humans efficiently inhibit human-A3G, whereas Vifs from SIVs
whose ancestors have not been transmitted to humans do not
(Gaddis et al., 2004). For A3G, the molecular basis for specificity
corresponds to Vif binding (Holmes et al., 2007b). For example,
HIV-1 Vif binds human-A3G but not A3G from AGMs; conversely,
SIV-AGM Vif binds AGM-A3G but not human A3G. Thus, the abil-
ity to overcome the APOBEC proteins of a recipient species cor-
relates with transmission potential, thus marking Vif as an impor-
tant determinant of lentivirus transmission. Importantly, A3G is
only one of a set of seven cytidine deaminase genes encoded
by a locus on human chromosome 22 (APOBEC3A-H), and the
anti-HIV-1 phenotypes of these other APOBEC proteins have
been extensively cataloged using cultured cell assays (Holmes
et al., 2007b). In sum, A3G has the most potent inhibitory effect
and A3F is also very active, while A3B is much less so. Of these,
A3B is not regulated by Vif and is barely expressed in T cells,
which suggests a lack of relevance in vivo for HIV-1 infections.
A3F, like A3G, is also linked to the cullin5-elonginB/C ligase by
Vif and correspondingly degraded (Table 1) (Liu et al., 2005). In-
terestingly, mutations have been described in Vif that segregate
the ability to downregulate A3G versus A3F (Russell and Pathak,
2007; Simon et al., 2005; Tian et al., 2006), implying that the
adaptation of HIV-1 to humans necessitated that Vif maintain at
least two distinguishable APOBEC3 binding interfaces.
Though A3G and A3F are each suppressed by Vif, there is
persuasive evidence to support their functional interaction with
HIV-1 during natural infections. Specifically, analyses of HIV-1
sequences from infected persons frequently reveal subsets of
sequences that are distinguished by excessive G-to-A hypermu-
tation (Janini et al., 2001). The local nucleotide sequence prefer-
ences for such mutations have been calculated and match those
determined for A3G (predominantly) and A3F in transfection-
based experiments (Holmes et al., 2007b), suggesting that these
APOBEC proteins are the most significant for driving HIV-1 hy-
permutation in vivo. Presumably, such sequences arise when
A3G/F occasionally escape Vif-mediated inhibition and become
encapsidated into viral particles.
Hypermutation, while clearly central to the profound impact of
A3G on HIV-1 infection, is not the only mechanism through which
antiviral effects are exerted. First, and noted originally by exam-ining deaminase-deficient proteins, infectivity can be reduced in
the absence of DNA editing (Newman et al., 2005). While not yet
entirely explained at the molecular level, these effects are asso-
ciated with diminished reverse transcription (Holmes et al.,
2007a; Iwatani et al., 2007; Mbisa et al., 2007). Second, and per-
haps mechanistically related, A3G residing in target cells (i.e., not
present in virions) has been reported to impede the synthesis of
viral DNA by incoming viral particles in quiescent T cells without
inducing hypermutation (Chiu et al., 2005). However, the relative
contributions of deamination-dependent versus -independent
effects of the APOBEC3 proteins during physiologic infections
remains unresolved and may well differ among different family
members (Holmes et al., 2007a; Miyagi et al., 2007; Schumacher
et al., 2008). A further area of uncertainty is the fate of the uridines
generated by deamination: it had been proposed that U residues
would be recognized by cellular DNA repair enzymes, perhaps
initiating viral DNA degradation, but the inhibition of such en-
zymes neither ameliorates the A3G antiviral phenotype nor pro-
motes the accumulation of viral DNA (Kaiser and Emerman,
2006; Langlois and Neuberger, 2008).
Different retroviruses have adopted different strategies to
evade suppression by APOBEC proteins. Human T cell leukemia
virus type 1, like HIV-1, replicates in CD4 T cells but averts signif-
icant inhibition by not packaging A3G into virions through the ac-
tion of sequences in the nucleocapsid (NC) region of Gag, thus
avoiding the need for a Vif-like factor (Derse et al., 2007). In con-
trast, the HIVs and SIVs have adopted the more elaborate tactic
of acquiring an additional regulatory protein, namely Vif. Be-
cause a regulatory interaction has the potential to be variable
in its extent, sporadic partial inhibition of A3G/F by Vif (e.g.,
through variation in either A3G/F expression or Vif sequences
[Simon et al., 2005]) may allow sufficient levels of these proteins
to survive and confer low levels of editing. Rather than being det-
rimental for the virus in the way that hypermutation is, this has the
potential to afford the virus an additional mechanism for promot-
ing beneficial sequence diversification that could, for instance,
facilitate escape from adaptive immunity or help drive pheno-
typic changes in the virus: indeed, detailed analyses of recently
transmitted viruses indicate that A3G/F can contribute to single-
nucleotide sequence variation (Keele et al., 2008). Population
level studies of HIV-1 infected cohorts also support the notion
that the balance between APOBEC proteins and their downregu-
lation by Vif is dynamic and subject to variation: specifically,
there is evidence that genetic polymorphisms in A3G or cullin5
are associated with differences in the rates of disease progres-
sion (An et al., 2007).
As potential DNA mutagens, especially those that accumulate
in the nucleus (A3A, A3B, and A3C), it seems intuitive that APO-
BEC3 protein function would be negatively regulated in some
manner in the absence of viral infection to protect against dele-
terious mutation of cellular genomic DNA. Conversely, some
level of constitutive expression may be necessary to control
the movement of the many endogenous retroviruses and retro-
transposons (LTR and non-LTR types such as LINE-1 and Alu el-
ements) that have been shown to be inhibited to various degrees
(and in different ways) by many APOBEC3 proteins (Esnault
et al., 2005; Holmes et al., 2007b). Such questions of fine-tuning
are starting to receive attention: enzymatic measurements have
shown that T cells tightly control A3G mediated deaminationCell Host & Microbe 3, June 2008 ª2008 Elsevier Inc. 393
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the association of A3G with an array of cytoplasmic ribonucleo-
protein complexes that localize to important sites of RNA func-
tion, storage, and metabolism can also modulate enzymatic ac-
tivity (Chiu et al., 2005, 2006; Gallois-Montbrun et al., 2007;
Kozak et al., 2006; Wichroski et al., 2006). Among A3G’s (and
A3F’s) interactions with cellular proteins, those with the Argo-
naute proteins, the effector components of RNA-induced silenc-
ing complexes, are notable (Gallois-Montbrun et al., 2007, 2008;
Wichroski et al., 2006). Whether APOBEC proteins are therefore
able to modulate RNA silencing pathways and translational reg-
ulation (Huang et al., 2007), and what possible connections there
may be to cellular function and/or HIV-1 replication, remains
largely unexplored (readers should refer to the accompanying
Review by Gottwein and Cullen on page 375 that discusses
interactions between viruses, microRNAs, and RNA silencing).
Primates have a total of eleven APOBEC genes, yet birds and
fish have only two each, which suggests that evolutionary pres-
sures have driven the expansion of this gene family (Conticello
et al., 2005; Harris and Liddament, 2004). Moreover, compari-
sons among the A3G sequences of a large panel of diverse pri-
mates revealed that these genes have been subject to nearly
constant severe positive selection throughout the past 33 million
years of primate evolution (Sawyer et al., 2004) and comparison
of the entire cluster of APOBEC3 genes indicates that most of
them have rapidly evolved since human-chimpanzee speciation
(Sawyer et al., 2004). What could have applied such pressures?
Since many retroviruses and retrotransposons, as well as hepa-
titis B virus, can be inhibited by APOBEC3 family members
(Holmes et al., 2007b), and the human genome contains active
LINE-1 and Alu elements, it is likely that the APOBEC3 genes
have evolved to defend against genomic assaults by a broad
spectrum of retrovirus-like parasites. Given that many of the
APOBEC3 proteins are expressed in the testes and/or ovaries
(e.g., Jarmuz et al., 2002), this appears, perhaps not unexpect-
edly, to be of particular importance for the protection of germ-
line. Recent results showing that two very different DNA viruses,
adeno-associated virus and human papillomavirus, can be in-
hibited or subjected to G-to-A editing, respectively, by APO-
BEC3 proteins reveals that the range of substrates for these en-
zymes extends beyond those requiring reverse transcription
(Chen et al., 2006; Vartanian et al., 2008). It will be fascinating
to see how many additional classes of virus are also targeted
by APOBEC proteins, either as inhibitors of replication or as
sources for sequence variation, and to determine whether
such effects are subjected to regulation by proteins analogous
to Vif.
Modulation of the Intracellular Environment: Vpr
Vpr is a 96 amino acid protein that is packaged into mature vi-
rions, but whose function has been difficult to elucidate. Vpr is
cytopathic to cells, although there has been some debate as to
whether or not the cell death is apoptotic (Muthumani et al.,
2005) or necrotic (Sakai et al., 2006). However, the whole ques-
tion of whether or not HIV-1-induced cyopathicity is important for
its pathogenesis has been called into question with recent find-
ings made during nonpathogenic infections of natural sooty
mangabey (SM) or AGM hosts with SIV-SM or SIV-AGM, respec-
tively, where the turnover time of infected cells was found to be
just as short as seen in HIV-1 infection of humans (Gordon et al.,394 Cell Host & Microbe 3, June 2008 ª2008 Elsevier Inc.2008; Pandrea et al., 2008). Nevertheless, one unambiguous at-
tribute of Vpr expression is its ability to delay or arrest cells in the
G2 phase of the cell cycle. The bulk of the data indicates that the
cell death phenotype induced by Vpr is linked to the pathway
leading to G2 arrest (Andersen et al., 2006), but in some culture
systems those two phenotypes might be independent (Bolton
and Lenardo, 2007). These differences notwithstanding, the pre-
sumed relevance of the ability of Vpr to cause a G2 cell-cycle ar-
rest is illustrated not only by its conservation among the HIV and
SIV Vpr proteins, but also by the observation that infected cells
in HIV-1 infected people appear to be enriched for cells in G2
(Zimmerman et al., 2006).
The distal events that lead to G2 arrest by Vpr appear to mimic
a DNA stress/damage checkpoint arrest by involving the DNA
damage-sensing kinase ATR (Zimmerman et al., 2004). How-
ever, since Vpr does not appear to cause DNA damage directly
(Lai et al., 2005), it was not immediately clear how the pathway
became activated in the first place. A flurry of recent papers
has provided some important clues. Mass spectrometry and
protein-protein interaction assays revealed that Vpr, like Vpu
and Vif, engages a cullin-RING ubiquitin ligase (Table 1; Figure 2).
In this case, it is the cullin4A-DDB1 complex, with Vpr making
contact via a receptor called DCAF1 (originally VprBP) that links
it to DDB1 (Belzile et al., 2007; DeHart et al., 2007; Hrecka et al.,
2007; Le Rouzic et al., 2007; Schrofelbauer et al., 2007; Tan
et al., 2007; Wen et al., 2007). Experiments showing that prevent-
ing Vpr’s interaction with DCAF1 or inhibiting DCAF1 expression
using RNAi both block Vpr-induced G2 arrest attest to the signif-
icance of the cullin4A-DDB1-DCAF1-Vpr complex (Dehart and
Planelles, 2008).
Interestingly, DCAF1 was also identified as an HIV-1-depen-
dency factor (i.e., a protein whose expression promotes replica-
tion) in a large-scale siRNA screen using a viral strain that was
deficient for Vpr (Brass et al., 2008). This suggests that the cull-
in4A-DDB1-DCAF1 complex is involved in an important step of
the viral life cycle, and that the role of Vpr might be to stabilize
the normal activity of the complex in a way that benefits the virus.
Supporting this, recent data show that the binding of Vpr to cull-
in4A-DDB1-DCAF1 augments its activity and is associated with
an increase in cullin4A neddylation—a posttranslational modifi-
cation with the ubiquitin-like protein Nedd8 that stimulates cullin
ligase function by facilitating E2 recruitment (Hrecka et al., 2007).
If this hypothesis is correct, then it becomes very important to
identify the relevant substrates of the cullin4A-DDB1-DCAF1
complex, to determine how their (presumed) degradation affects
HIV-1, and to resolve whether Vpr acts simply to improve the
efficiency of this process.
Rather than increasing the activity of the cullin4A-DDB1-
DCAF1 complex toward normal substrates, an alternative model
is that Vpr recruits a novel substrate (whose expression is neces-
sary for cell-cycle progression) for ubiquitylation (and degrada-
tion). Evidence supporting this view comes from the finding
that some mutations in the C terminus of Vpr do not affect bind-
ing to DCAF1, but abolish Vpr-triggered G2 arrest. Given that
such proteins are dominant inhibitors of cell-cycle arrest induced
by wild-type Vpr (DeHart et al., 2007; Le Rouzic et al., 2007), the
simplest explanation is that the C terminus of Vpr recruits a novel
substrate to the cullin4A-DDB1-DCAF1 for ubiquitylation (Fig-
ure 2). It is not known what this substrate could be; determining
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scribed for Vpr, or awaits identification, will be central to under-
standing the effect of Vpr on the cell cycle.
In addition to G2 arrest, HIV-1 Vpr also facilitates infection of
macrophages. Earlier data attributed this effect to the stimulation
of viral nuclear import, but this model has not held up (Yamashita
and Emerman, 2005). Viruses of the HIV-2/SIV-SM phylogenetic
lineage encode both Vpr and a paralog, Vpx, whereas HIV-1 and
the SIVs of the remaining lineages encode just Vpr. The two main
functions of HIV-1 Vpr are segregated in HIV-2/SIV-SM with Vpr
causing cell-cycle arrest and Vpx being important for the infec-
tion of macrophages, though HIV-2/SIV-SM Vpx seems to be
much more important for macrophage infection than HIV-1
Vpr. Indeed, recent studies on Vpx may have provided key in-
sight into the ultimate role of Vpr in the viral life cycle: specifically,
HIV-2/SIV-SM vectors can only infect macrophages or mono-
cyte-derived dendritic cells efficiently if the vpx gene is intact
(Goujon et al., 2007; Sharova et al., 2008). Moreover, the Vpx
protein can be supplied in trans to allow macrophage or dendritic
cell infection and, in fact, can be added to allow HIV-1, as well as
more distantly related retroviruses, to infect these cells (Goujon
et al., 2007; Sharova et al., 2008). In this respect, Vpx appears
to act in a somewhat analogous way that excess viral capsids
can be added to cells to saturate the host restriction factor,
TRIM5a (Towers, 2007).
Importantly, Vpx, like Vpr, binds to DCAF1 (Le Rouzic et al.,
2007; Srivastava et al., 2008), and the ability of Vpx to interact
with the same cullin4A-DDB1-DCAF1 complex as Vpr is essen-
tial for promoting SIV-SM infection of macrophages (Sharova
et al., 2008; Srivastava et al., 2008). Thus, a plausible explanation
for the effect of Vpx on the early stages of macrophage infection
is that it is introduced into cells by virtue of its association with
incoming viral cores and then interacts with a host defense
protein to target that protein to cullin4A-DDB1-DCAF1 for elimi-
nation (Figure 2). This notion is further supported by cell-fusion
experiments in which macrophages were shown to harbor
a dominantly acting, but Vpx-sensitive, repressor of SIV-SM
infection (Sharova et al., 2008).
Whether HIV-1 Vpr also interacts with this putative restriction
factor, and whether this factor plays a role in Vpr-induced G2 ar-
rest, will only be answered once its identity is resolved. While G2
arrest by Vpr can be rationalized by the finding that HIV-1 tran-
scription is more active in G2 (and therefore more virus is pro-
duced) (Goh et al., 1998), it is also possible that G2 arrest is an
unavoidable by-product of the destruction of a host protein
that plays one role in cell-cycle progression and another in
host-mediated protection against viruses. Indeed, evolutionary
analysis suggests that such a class of host genes that both act
in the DNA-repair pathway in nonhomologous end joining and
also show evolutionary signs of pathogen defense genes (be-
cause of they are under positive selection) does exist in yeast
(Sawyer and Malik, 2006). Moreover, there is precedence with
the V protein of paramyxoviruses, which also binds to DDB1,
and although the mechanism is entirely different, also causes
both cell-cycle arrest and is involved in abrogation of host de-
fense through interference with interferon signaling (Horvath,
2004). Thus, while speculative at this time, it is possible that cer-
tain proteins that are involved in DNA repair or cell-cycle pro-
gression may also serve a dual purpose in host antiviral defense,and that these are targeted by Vpr for degradation. If true, then
this implies that Vpr, like Vif and Vpu, is fundamentally a viral
countermeasure to host-mediated restriction.
Conclusion
While HIV-1 is a relatively new human infection, human ances-
tors have been infected with retroviruses for many millions of
years. We know this because nearly 8% of the human genome
is comprised of endogenous retroviruses (Bannert and Kurth,
2004), of which at least some of each family must have been
the result of an exogenous retroviral infection that entered the
germline and then became fixed within the species. Many of
these infections are quite old (over 25 million years), but episodic
infections have continued even since human/chimpanzee speci-
ation (Bannert and Kurth, 2004). Thus, host defenses that are
operative against HIV-1 were not selected to inhibit this virus.
Rather, they were likely selected to work against much more
ancient viral infections. HIV-1, on the other hand, must have
adapted to humans (or more likely to hominoids since HIV-1 itself
is a direct descendant of similar chimpanzee and gorilla viruses)
through the evolution of viral genes that allowed it to replicate in
the face of ancient antiviral defense mechanisms. As these
defenses are still active, finding ways to stabilize or derepress
them in the presence of the HIV-1 accessory proteins is a poten-
tial strategy for antiviral drug development that would turn the
naturally hostile environment of human cells into a more effective
one for viral control.
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